The National Eye Institute was established in 1968 as the federal government's lead agency for vision research. As NEI Director Michael F. Chiang, MD, has noted, almost every breakthrough in preventing blindness in the past 50 years has been NEI-supported — including the development of optical coherence tomography, anti-VEGF treatments for macular degeneration, the first FDA-approved gene therapy targeting an inherited disease (Luxturna, for an inherited retinal disorder), and the first FDA-authorized autonomous AI diagnostic tool for diabetic retinopathy screening. Vision loss already costs the U.S. economy nearly $200 billion annually in medical care and lost productivity.
Proposals to restructure the NIH have emerged in two waves. In June 2024, the House Energy and Commerce Committee released a framework proposing to consolidate the NIH's 27 institutes and centers into 15, folding the NEI into a broader "National Institute of Neuroscience and Brain Research" alongside the National Institute of Dental and Craniofacial Research and the National Institute of Neurological Disorders and Stroke. The vision community mobilized swiftly in opposition.
The Trump administration's proposed FY2026 federal budget escalated this threat significantly, proposing to cut NIH funding by approximately 40% and consolidate its 27 institutes into just eight. Under this plan, the NEI would be folded into a new neuroscience-focused institute. The proposal was met with unified opposition from the ophthalmology and vision research communities.
In a significant advocacy victory, both the House and Senate FY2026 spending bills maintained funding for all 27 NIH institutes and centers, rejecting the administration's restructuring proposal.